An Open-label, Multicenter Extension Study to Evaluate the Long-term Safety and Tolerability of LUM001, an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTi), in Patients With Primary Biliary Cirrhosis

Trial Profile

An Open-label, Multicenter Extension Study to Evaluate the Long-term Safety and Tolerability of LUM001, an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTi), in Patients With Primary Biliary Cirrhosis

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 30 Jul 2015

At a glance

  • Drugs Lopixibat chloride (Primary)
  • Indications Primary biliary cirrhosis
  • Focus Adverse reactions
  • Acronyms CASCADE
  • Sponsors Lumena Pharmaceuticals; Shire
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 27 Jul 2015 Status changed from not yet recruiting to withdrawn prior to enrolment as per ClinicalTrials.gov record.
    • 18 Mar 2015 Planned initiation date changed from 1 Mar 2015 to 1 May 2015 as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top